Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review - PubMed (original) (raw)
Review
Cholangiocarcinoma in Patients with Primary Sclerosing Cholangitis (PSC): a Comprehensive Review
Junmin Song et al. Clin Rev Allergy Immunol. 2020 Feb.
Abstract
Cholangiocarcinoma (CCA) is the most common malignancy in patients with primary sclerosing cholangitis (PSC) and carries a high rate of mortality. Although the pathogenesis of CCA in PSC is largely unknown, inflammation-driven carcinogenesis concomitant with various genetic and epigenetic abnormalities are underlying factors. The majority of CCA cases develop from a dominant stricture (DS), which is defined as a stricture with a diameter < 1.5 mm in the common bile duct or < 1.0 mm in the hepatic duct. In PSC patients presenting with an abrupt aggravation of jaundice, pain, fatigue, pruritus, weight loss, or worsening liver biochemistries, CCA should be suspected and evaluated utilizing a variety of diagnostic modalities. However, early recognition of CCA in PSC remains a major challenge. Importantly, 30-50% of CCA in PSC patients are observed within the first year following the diagnosis of PSC followed by an annual incidence ranging from 0.5 to 1.5 per 100 persons, which is nearly 10 to 1000 times higher than that in the general population. Cumulative 5-year, 10-year, and lifetime incidences are 7%, 8-11%, and 9-20%, respectively. When PSC-associated CCA is diagnosed, most tumors are unresectable, and no effective medications are available. Given the poor therapeutic outcome, the surveillance and management of PSC patients who are at an increased risk of developing CCA are of importance. Such patients include older males with large-duct PSC and possibly concurrent ulcerative colitis. Thus, more attention should be paid to patients with these clinical features, in particular within the first year after PSC diagnosis. In contrast, CCA is less frequently observed in pediatric or female PSC patients or in those with small-duct PSC or concurrent Crohn's disease. Recently, new biomarkers such as antibodies to glycoprotein 2 have been found to be associated with an increased risk of developing CCA in PSC. Herein, we review the literature on the pathogenesis, incidence, clinical features, and risk factors, with a focus on various diagnostic modalities of PSC-associated CCA.
Keywords: Cholangiocarcinoma; Diagnosis; Dominant stricture; Epidemiology; Incidence; Inflammatory bowel disease; Primary sclerosing cholangitis; Risk factor; Surveillance; Ulcerative colitis.
Similar articles
- Screening and diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis.
Jesudian AB, Jacobson IM. Jesudian AB, et al. Rev Gastroenterol Disord. 2009 Spring;9(2):E41-7. Rev Gastroenterol Disord. 2009. PMID: 19668124 Review. - Pathogenesis, diagnosis and treatment of premalignant and malignant stages of cholangiocarcinoma in primary sclerosing cholangitis.
Grimsrud MM, Folseraas T. Grimsrud MM, et al. Liver Int. 2019 Dec;39(12):2230-2237. doi: 10.1111/liv.14180. Epub 2019 Oct 8. Liver Int. 2019. PMID: 31216595 Review. - Primary sclerosing cholangitis-associated cholangiocarcinoma: special considerations and best practices.
Fung BM, Tabibian JH. Fung BM, et al. Expert Rev Gastroenterol Hepatol. 2021 May;15(5):487-496. doi: 10.1080/17474124.2021.1900732. Epub 2021 Apr 19. Expert Rev Gastroenterol Hepatol. 2021. PMID: 33682586 Review. - Cholangiocarcinoma in patients with primary sclerosing cholangitis.
Fung BM, Tabibian JH. Fung BM, et al. Curr Opin Gastroenterol. 2020 Mar;36(2):77-84. doi: 10.1097/MOG.0000000000000616. Curr Opin Gastroenterol. 2020. PMID: 31850928 Review. - Cholangiocarcinoma Surveillance Recommendations in Patients with Primary Sclerosing Cholangitis.
Saca D, Flamm SL. Saca D, et al. Clin Liver Dis. 2024 Feb;28(1):183-192. doi: 10.1016/j.cld.2023.07.010. Epub 2023 Aug 28. Clin Liver Dis. 2024. PMID: 37945159 Review.
Cited by
- Imaging of Benign Biliary Tract Disease.
Ghuman SS, Buxi TBS, Jain K, Rawat KS, Yadav A, Sud S. Ghuman SS, et al. Indian J Radiol Imaging. 2024 May 3;34(4):726-739. doi: 10.1055/s-0044-1786038. eCollection 2024 Oct. Indian J Radiol Imaging. 2024. PMID: 39318553 Free PMC article. Review. - Spatial transcriptomics profiling of gallbladder adenocarcinoma: a detailed two-case study of progression from precursor lesions to cancer.
Pirenne S, Manzano-Núñez F, Loriot A, Cordi S, Desmet L, Aydin S, Hubert C, Toffoli S, Limaye N, Sempoux C, Komuta M, Gatto L, Lemaigre FP. Pirenne S, et al. BMC Cancer. 2024 Aug 20;24(1):1025. doi: 10.1186/s12885-024-12770-0. BMC Cancer. 2024. PMID: 39164619 Free PMC article. - Interleukin-1β: Friend or foe for gastrointestinal cancers.
Khawkhiaw K, Panaampon J, Imemkamon T, Saengboonmee C. Khawkhiaw K, et al. World J Gastrointest Oncol. 2024 May 15;16(5):1676-1682. doi: 10.4251/wjgo.v16.i5.1676. World J Gastrointest Oncol. 2024. PMID: 38764841 Free PMC article. - What is the appropriate method of pathological specimen collection for cholangiocarcinoma detection in primary sclerosing cholangitis?
Kano Y, Ishikawa T, Yamao K, Mizutani Y, Iida T, Uetsuki K, Yamamura T, Furukawa K, Nakamura M, Kawashima H. Kano Y, et al. J Gastroenterol. 2024 Jul;59(7):621-628. doi: 10.1007/s00535-024-02105-y. Epub 2024 May 7. J Gastroenterol. 2024. PMID: 38713262 - STAT activation in regulatory CD4+ T cells of patients with primary sclerosing cholangitis.
Dold L, Kalthoff S, Frank L, Zhou T, Esser P, Lutz P, Strassburg CP, Spengler U, Langhans B. Dold L, et al. Immun Inflamm Dis. 2024 Apr;12(4):e1248. doi: 10.1002/iid3.1248. Immun Inflamm Dis. 2024. PMID: 38607233 Free PMC article.
References
- PLoS One. 2015 Oct 02;10(10):e0139305 - PubMed
- Hepatology. 2016 Oct;64(4):1178-88 - PubMed
- Hepatology. 2017 Mar;65(3):907-919 - PubMed
- Clin Rev Allergy Immunol. 2016 Jun;50(3):390-403 - PubMed
- Liver Int. 2008 Aug;28(7):983-9 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical